Brain natriuretic peptide and HIV-related cardiomyopathy

AIDS Reader

Volumn 12, Issue 11, 2002, Pages 501-508

  Carrillo Jimenez, Rodolfo ^a   Treadwell, Thomas L ^b   Goldfine, Harvey ^c   Buenano, Alvaro ^a   Lamas, Gervasio A ^a,d   Hennekens, Charles H ^a,d  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Division of Infectious Diseases   (United States)

^c METROWEST MEDICAL CENTER   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Brain natriuretic peptide; Cardiomyopathy; Echocardiography; HIV AIDS; Screening

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COTRIMOXAZOLE; DIGOXIN; LISINOPRIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CARDIOMEGALY; CARDIOMYOPATHY; CASE REPORT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PNEUMOCYSTIS PNEUMONIA;

ADULT; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN;

EID: 0036853549     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med. 1999;134:437-444.
2. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-1353.
3. Yamamoto K, Burnett JC Jr, Bermudez EA, et al. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail. 2000;6:194-200.
4. Suzuki T, Yamaoki K, Nakajima O, et al. Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels. Jpn Heart J. 2000;41:205-214.
5. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13.
6. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37:379-385.
7. DeCastro S, Migliau G, Silvestri A, et al. Heart involvement in AIDS: A prospective study during various stages of the disease. Eur Heart J. 1992;13:1452-1459.
8. Rerkpattanapipat P, Wongpraparut N, Jacobs LE, Kotler MN. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med. 2000; 160:602-608.
9. Yunis NA, Stone VE. Cardiac manifestations of HIV/AIDS: A review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:145-154.
10. Michaels AD, Lederman RJ, MacGregor JS, Cheitlin MD. Cardiovascular involvement in AIDS. Curr Probl Cardiol. 1997,22:111-148.
11. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses. 1998;14:1071-1077.
12. Lewis W. Cardiomyopathy in AIDS: A pathophysiological perspective. Prog Cardiovasc Dis. 2000;43:151-170.
13. Herskowitz A. Cardiomyopathy and other symptomatic heart diseases associated with HIV infection. Curr Opin Cardiol. 1996;11:325-331.
14. Carrillo-Jimenez R, Lamas GA, Hennekens CH. Plasma markers of brain natriuretic peptide: A potential marker for HIV-related cardiomyopathy. J Cardiovasc Pharmacol Ther. 2002;7:135-137.
15. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. N Engl J Med. 1998;339:1093-1099.
16. Herskowitz A, Vlahov D, Willoughby S, et al. Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am J Cardiol. 1993;71:955-958.
17. Segal BH, Factor SM. Myocardial risk factors other than human immunodeficiency virus infection may contribute to histologic cardiomyopathic changes in acquired immune deficiency syndrome. Mod Pathol. 1993;6:560-564.
18. Stevenson LW. The limited availability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884-888.
19. Akhras F, Durbey S, Gazzard B, Noble MI. Emerging patterns of heart disease in HIV infected homosexual subjects with and without opportunistic infections; a prospective color flow Doppler echocardiographic study. Eur Heart J. 1994;15:68-75.
20. Corallo S, Mutinelli MR, Moroni M, et al. Echocardiography detects myocardial damage in AIDS: Prospective study in 102 patients. Eur Heart J. 1988;9:887-892.
21. Shannon RP, Simon MA, Mathier MA, et al. Dilated cardiomyopathy associated with simian AIDS in nonhuman primates. Circulation. 2000;101:185-193.
22. Shannon RP. SIV cardiomyopathy in non-human primates. Trends Cardiovasc Med. 2001;11:242-246.
23. Lewis W, Grupp IL, Grupp G, et al. Cardiac dysfunction occurs in the HIV-1 transgerdc mouse treated with zidovudine. Lab Invest. 2000;80:187-197.
24. Carnio EC, Jankowski M, Mukaddam-Daher S, et al. Elevated levels of natriuretic peptides in lungs of hamsters with genetic cardiomyopathy. Regul Pept. 1997;70:67-73.
25. Hennekens CH, Buring J, Mayrent SL, eds. Epidemiology in Medicine. Boston: Little Brown & Co Inc; 1987.